In Vitro Diagnostics (IVD) and Medical Device Lifecycle Management

In Vitro Diagnostics (IVD) and Medical Device Lifecycle Management: Continuous monitoring, updating, and alignment of key medical regulatory documents—such as Clinical Evaluation Reports (CERs), Performance Evaluation Reports (PERs), Periodic Safety Update Reports (PSURs), and Post Market Surveillance Reports (PMSRs)—are essential at every stage of a medical device or IVD’s lifecycle.

Lifecycle management touches every area of development and commercialization, including early design, clinical and performance evaluation, regulatory submissions, market launch, and long term post market monitoring.

With extensive experience in end to end lifecycle documentation and compliance, Masuu Global Solutions delivers high quality medical writing and regulatory support for both medical devices and IVDs—ensuring timely updates, consistent traceability, and full compliance with global regulatory frameworks.

IVD & Medical Device Lifecycle Management – Overview

Lifecycle management for medical devices and IVDs is a structured, continuous process that spans:
  • Early stage research & design
  • Scientific validity assessment
  • Clinical & performance evaluations
  • Compilation of regulatory submissions
  • Post market surveillance (PMS), PMCF, PMPF
  • Ongoing updates to technical documentation

The objective is to ensure that devices remain safe, effective, and compliant throughout their entire commercial lifespan.

Medical writing plays a pivotal role by converting scientific, analytical, and clinical data into clear, regulator ready documentation. This includes key deliverables such as:
  • CEP, CER, PER, PEP
  • PMSR, PMSP, PSUR
  • PMCF & PMPF plans and reports
  • SVR, CPR, APR
  • SSP, SSCP

Consistent, compliant documentation not only supports regulatory approvals but also strengthens transparency, enhances real world safety evaluation, and maintains robust evidence to satisfy global healthcare authorities.

When executed well, lifecycle management provides manufacturers with a future proof compliance framework, reducing risk, strengthening global credibility, and supporting sustainable market success across the EU, U.S., UK, APAC, LATAM, and beyond.

Importance of Lifecycle Management & Reporting

Effective lifecycle management ensures that devices continually meet global safety and performance expectations. Key benefits include:
  • Continuous compliance with EU MDR, EU IVDR, FDA, UKCA, and other global regulations
  • Timely updates to critical reports (CERs, PERs, PMSRs, PSURs)
  • Early detection of safety issues, trends, and performance signals
  • Fewer regulatory findings and faster approvals
  • Audit ready documentation that withstands NB and authority scrutiny
  • Enhanced real world evidence integration for better decision making
  • Stronger long term product safety and performance monitoring

Reports That Require Periodic Updating

Clinical Evaluation Reports (CERs)

Updated periodically to incorporate:
  • New literature
  • PMS findings
  • PMCF data
  • Vigilance signals

Required under EU MDR and global frameworks.

Performance Evaluation Reports (PERs)

Updated to reflect:
  • Advances in analytical methods
  • Manufacturing changes
  • Updated scientific validity
  • Evolving clinical practice

Clinical & Analytical Performance Reports (CPRs & APRs)

Ensure that IVD performance metrics—sensitivity, specificity, precision, accuracy—remain aligned with intended use.

Scientific Validity Reports (SVRs)

Updated as scientific understanding evolves and new evidence emerges.

Periodic Safety Update Reports (PSURs)

Provide updated benefit risk profiles, performance trends, and safety summaries. PSURs are central to MDR/IVDR lifecycle compliance.

Post Market Surveillance Reports (PMSRs)

Include PMCF/PMPF updates, complaint trends, vigilance data, and real world performance insights.

Together, these documents form a continuous lifecycle evidence ecosystem required for global market access and long term compliance.

Masuu Global Solutions – Lifecycle Management Expertise

Our Expertise Includes:

  • CEP / CER development & updates
  • PEP / PER development & maintenance
  • Clinical Performance Reports (CPR)
  • Analytical Performance Reports (APR)
  • Scientific Validity Reports (SVR)
  • Summary of Safety & Performance (SSP)
  • Summary of Safety & Clinical Performance (SSCP)
  • Lifecycle management of all medical writing deliverables
  • Gap analyses of CERs, PERs, and supporting documentation
  • PMS Plans & PMS Reports
  • PMCF & PMPF Plans and Reports
  • PSUR preparation and updates
  • Addressing NB comments and corrective updates
  • Full regulatory documentation lifecycle support

Advantages of Partnering with Masuu

  • Full compliance with EU MDR, IVDR, FDA, UKCA, and global regulations
  • Dedicated teams of medical device and IVD specialists
  • Tailored lifecycle management solutions to match product class and market strategy
  • End to end resource and staffing augmentation
  • Cross functional regulatory, clinical, and scientific insights
  • Efficient processes ensuring fast turnaround and high quality deliverables

Frequently Asked Questions

Medical device and IVD lifecycle management is the continuous process of maintaining safety, performance, clinical or performance evidence, and regulatory documentation throughout a product’s lifecycle. It covers design, evaluation, regulatory submissions, market launch, post-market surveillance, PMCF or PMPF, and periodic updates to technical and clinical documentation.

A Clinical Evaluation Report (CER) should be maintained and updated when new information could affect the clinical evaluation or benefit–risk conclusions. Relevant inputs include new literature, PMS findings, PMCF results, vigilance signals, and product or regulatory changes. The update approach should reflect the device’s characteristics, risks, evidence, and applicable regulatory requirements.

An IVD Performance Evaluation Report should be reviewed and updated when new evidence, scientific developments, analytical methods, clinical practices, manufacturing changes, or performance information could affect the evaluation. Updates should maintain consistency between scientific validity, analytical performance, clinical performance, intended purpose, and the supporting technical documentation.

A CER evaluates the clinical safety and performance of a medical device, while a PER evaluates the scientific validity, analytical performance, and clinical performance of an IVD. PMSRs document post-market surveillance findings, whereas PSURs periodically summarize safety, performance, benefit–risk information, and relevant post-market data for applicable devices.

Post-market surveillance and Post-Market Clinical Follow-up provide real-world information that can influence the ongoing clinical evaluation. Relevant PMS trends, complaints, vigilance signals, and PMCF findings should be assessed and incorporated into the CER where appropriate. This helps ensure that clinical conclusions and benefit–risk assessments remain supported by current evidence.

Depending on the product and applicable requirements, lifecycle documentation may include CERs, PERs, PSURs, PMS reports, PMCF or PMPF plans and reports, and related clinical or performance evidence. IVD documentation can also include Scientific Validity Reports, Analytical Performance Reports, and Clinical Performance Reports. Updates should reflect new evidence and post-market information.

IVD performance should be continuously evaluated using relevant analytical and clinical evidence generated throughout the product lifecycle. Performance information such as sensitivity, specificity, precision, and accuracy should remain consistent with the intended purpose and current evidence. New scientific information, manufacturing changes, PMS findings, and PMPF data may require documentation updates.

Post-market surveillance provides ongoing information about a device’s safety and performance after commercialization. Complaint trends, vigilance data, PMCF or PMPF findings, and real-world performance information can identify emerging risks or changes in device performance. These findings may trigger updates to clinical evaluations, performance reports, risk assessments, PMS documentation, or other regulatory records.

Lifecycle documentation should use controlled, traceable information across clinical, regulatory, quality, and post-market processes. Changes to intended purpose, risks, clinical evidence, performance data, or regulatory requirements should be assessed for their impact on related documents. Maintaining clear traceability between CERs, PERs, PMS, PMCF/PMPF, PSURs, and technical documentation helps prevent inconsistencies.

New regulatory requirements, scientific evidence, clinical literature, safety signals, or product changes should be assessed for their impact on existing documentation and compliance. Depending on the findings, manufacturers may need to update clinical or performance evaluations, PMS documentation, risk assessments, technical files, labeling, or other regulatory records to maintain continued compliance.

Book a Demo